Gastric electrical stimulation treatment of type 2 diabetes: Effects of implantation versus meal-mediated stimulation. a randomized blinded cross-over trial

Physiological Reports

Volumn 3, Issue 7, 2015, Pages

  Lebovitz, Harold E ^a   Ludvik, Bernhard ^b   Kozakowski, Jaroslaw ^c   Tarnowski, Wieslaw ^d   Zelewski, Mateusz ^e   Yaniv, Irit ^e   Schwartz, Tse’Ela ^f  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Orlowski Hospital Warsaw   (Poland)

^d BIELANSKI HOSPITAL   (Poland)

^e MetaCure (USA) Inc   (United States)

^f Biostatistics and Medical Device Research Division at GCP Clinical Studies   (Israel)

Author keywords

Gastric electrical stimulation; Glycemic control; Gut brain axis; Hemoglobin A1c; Placebo effect

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; ELECTROSTIMULATION; FEMALE; GASTRIC ELECTROSTIMULATION; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; YOUNG ADULT;

EID: 84991003343     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12456     Document Type: Article

References (20)

1. ADA, EASD, IFCC, IDF. 2007. Consensus statement on the worldwide standardization of the HbA1c measurement. Diabetologia 50:2042-2043.
2. Banerji, M. A., R. L. Chaiken, and H. E. Lebovitz. 1996. Longterm normoglycemic remission in black newly diagnosed NIDDM subjects. Diabetes 45:337-341.
3. Behar, M. 2014. Invasion of the body hackers. Can the body be reprogrammed to fight disease with devices instead of drugs? The New York Times Magazine May 25.
4. Bhatt, D. L., D. E. Kandzari, W. W. O’Neill, R. D’Agostino, J. M. Flack, B. T. Katzen, et al. 2014. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 370:1393-1401.
5. Cazeau, S., C. Leclerco, T. Lavergne, S. Walker, C. Varma, C. Linde, et al. 2001. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delays. N. Engl. J. Med. 344:873-880.
6. Chen, H.-S., T.-E. Wu, T.-S. Jap, L.-C. Hsiao, S.-H. Lee, and H.-D. Lin. 2008. Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 31:1927-1932.
7. De Luca, M., G. Segato, L. Busetto, F. Favretti, F. Aigner, H. Weiss, et al. 2004. Progress in implantasble gastric stimulation: summary of results of the European multicentre study. Obes. Surg. 14(Suppl. 1):S33-S39.
8. Hollander, E., C. M. DeCaria, J. N. Finkell, T. Begaz, C. M. Wong, and C. Cartwright. 2000. A randomized double-blind Fluvoxamine/Placebo crossover trial in pathologic gambling. Biol. Psychiatry 47:813-817.
9. Ikramuddin, S., R. P. Blackstone, A. Brancatisano, J. Toouli, S. N. Shah, B. M. Wolfe, et al. 2014. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity. The recharge randomized clinical trial. JAMA 312:915-922.
10. Kaptchuk, T. J., P. Goldman, D. A. Stone, and W. B. Stason. 2000. Do medical devices have enhanced placebo effects? J. Clin. Epidemiol. 53:786-792.
11. Lebovitz, H. E., B. Ludvik, I. Yaniv, W. Haddad, T. Schwartz, and R. Aviv. 2013. Metacare Investigative Group. Fasting plasma triglycerides predict the glycaemic response to treatment of type 2 diabetes by gastric electrical stimulation. A novel lipotoxicity paradigm. Diabet. Med. 30:687-693.
12. Lebovitz, H. E., B. Ludvik, I. Yaniv, T. Schwartz, M. Zelewski, and D. D. Gutterman. 2015. Treatment of patients with obese type 2 diabetes with Tantalus-DIAMOND_gastric electrical stimulation: normal triglycerides predict durable effects for at least 3 years. Horm. Metab. Res. 47:456-462.
13. Peles, S., J. Petersen, R. Aviv, S. Policker, O. Abu-Hatoum, S. A. Ben-Haim, et al. 2003. Enhancement of antral contractions and vagal afferent signaling with synchronized electrical stimulation. Am. J. Physiol. Gastrointest. Liver Physiol. 285:G577-G585.
14. Sanmiguel, C. P., W. Haddad, R. Aviv, S. A. Cunneen, E. H. Phillips, W. Kapella, et al. 2007. The TANTALUSTM system for obesity: effect on gastric emptying of solids and ghrelin plasma levels. Obes. Surg. 17:1-6.
15. Sanmiguel, C., J. L. Conklin, S. A. Cunneen, P. Barnett, E. H. Phillips, M. Kipnes, et al. 2009. Gastric electrical stimulation with the TANTALUS system in obese type 2 diabetes patients: effect on weight and glycemic control. J. Diabetes Sci. Technol. 3:964-970.
16. Sarr, M. G., C. J. Billington, R. Brancatisano, A. Brancatisano, J. Toouli, L. Kow, et al. 2012. The EMPOWER study: randomized, prospective, double blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity. Obes. Surg. 22:1771-1782.
17. Satterthwaite, F. E. 1946. An approximate distribution of estimates of variance components. Biometrics 2:110-114.
18. Senn, S.. 2002. Cross-over trials in clinical research, 2nd edn. Publisher John Wiley & Sons, Hoboken, NJ, USA.
19. Shikora, S. A., R. Bergenstal, M. Bessler, F. Brody, G. Foster, A. Frank, et al. 2009. Implantable gastric stimulation for the treatment of clinically severe obesity: results of the SHAPE trial. Surg. Obes. Relat. Dis. 5:31-37.
20. Wong, S. K., A. P. Kong, R. Osaki, V. W. Ng, L. L. Chan, C. C. Lam, et al. 2015. A prospective case-control study to compare the efficacy of laparoscopic placement of gastric contraction modulator (TANTALUS II) vs supplementary insulin treatment in obese T2DM patients. Diabetes Technol. Ther. 17:283-290.